245 First Street
United States - Map
Zalicus Inc., a biopharmaceutical company, engages in the discovery and development of novel treatments for patients suffering from pain. The company develops Z160, a novel oral N-type calcium channel blocker that is under 2 Phase 2a clinical trials for the treatment of neuropathic pain, including post-herpetic neuralgia and lumbosacral radiculopathy; Z944, a novel oral T-type calcium channel blocker that has completed Phase 1 clinical studies for the treatment of pain indications; and Nav1.7 and Nav 1.8 types sodium channels for the treatment of acute and chronic inflammatory and neuropathic pain. It has collaboration agreements with Hydra Biosciences, Inc.; Mallinckrodt Inc.; Fovea Pharmaceuticals SA; Novartis; Amgen Inc.; and United States Army Medical Research Institute. The company was formerly known as CombinatoRx, Incorporated and changed its name to Zalicus Inc. in September 2010. Zalicus Inc. was founded in 2000 and is based in Cambridge, Massachusetts.
|Dr. Mark H. N. Corrigan M.D.,
Chief Exec. Officer, Pres and Director
|Mr. Justin A. Renz ,
Chief Financial Officer, Principal Accounting Officer, Exec. VP and Treasurer
|Mr. Jason F. Cole Esq.,
Exec. VP of Corp. Devel., Gen. Counsel and Sec.
|Dr. Terrance P. Snutch Ph.D., FRSC, DSc (hon),
Chief Scientific Officer and Sr. VP
|Ms. Gina Nugent ,
VP of Corp. Communications and Investor Relations
|Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|